Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract

BPC-PH2-UC — structured trial abstract

BPC-PH2-UC — BPC-157 in mucosal barrier: randomised, double-blind, placebo-controlled

Document identifier
CEI-TR-0111
Series
Trial abstract
Version
3.4
Published
15 Feb 2024
Last reviewed
15 Dec 2024
Next review
15 Dec 2026
Identifier
10.71829/cei.trial.111
Certainty
Not rated
Cycle
2024 Q1
Phase
Phase 2
Status
No retrievable report

§1Structured abstract

§1.1Objective

To evaluate BPC-157 in inflammatory bowel disease and mucosal barrier disorders, against the comparator specified in §2, with the primary endpoint stated below.

§1.2Design

Design
Randomised, double-blind, placebo-controlled, parallel-group
Masking
Double-blind (participant, investigator and sponsor)
Phase
Phase 2
Randomised participants
not recorded by the Institute
Duration of the primary analysis period
Not recorded
Sponsor class
Manufacturer-sponsored
Registry identifier
not reproduced — see the note in §1.5

§1.3Primary endpoint

Clinical remission in ulcerative colitis

§1.4Principal result

The Institute has identified references to a clinical programme under this compound but has not obtained a published report, and grades all human claims very low certainty on that basis.

§1.5Provenance of this abstract

Table 1. Field-by-field provenance. The Institute records which fields are extracted from a source and which are its own reconstruction, so that a reader can tell the two apart without leaving the page.

FieldProvenanceNote
Design, phase, duration, primary endpointExtractedReproduced from the published report or the registry record.
Randomised participantsNot heldNot recorded by the Institute. The field is left empty rather than estimated.
Principal resultExtractedReproduced as published, with the confidence interval where the Institute holds it.
Centres, countries and baseline characteristicsReconstructedDerived by the Institute from the design class and the randomised total. Presented in §2 as an illustrative operational profile and marked as such. These figures are not published characteristics of this trial.
Certainty assessmentInstitute judgementThe Institute’s own domain-by-domain assessment, with reasoning recorded against each domain in §4.
Registry identifierNot heldThe Institute does not reproduce a registry identifier it has not verified and never constructs one. Documents are referenced by the Institute’s own identifier.
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.